SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as investors discuss the potential impact of its AI robotics spinoff and VW partnership on the company's future. Community members are analyzing the stock's technical strength, debating short squeeze possibilities, and watching for a breakout. Broader EV sector trends and Rivian's progress towards profitability are also key talking points.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk ($NVO) is trending as investors debate the company's strategy amidst increased competition and a potential bidding war with Pfizer for Metsera. The community is discussing the implications of a possible White House deal on drug pricing and Medicare coverage, as well as the upcoming earnings report. Some traders express concerns about the stock's recent performance, while others see it as a long-term value play in the obesity and diabetes market.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

HOOD is trending as traders anticipate earnings, with many expecting strong numbers due to increased market activity and new offerings like prediction markets. The community is weighing bullish sentiment against potential profit-taking, especially given broader market uncertainty. Some traders also speculate about potential partnerships and the impact of crypto trends on Robinhood's performance.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending amid community excitement around its AI-driven automation platform and recent ISO certification, which validates its AI governance. Discussions revolve around its partnerships with major tech companies like Microsoft and Nvidia, with some anticipating a potential acquisition. Despite positive developments, concerns persist regarding the CEO's ongoing share sales, creating mixed sentiment.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riot Blockchain Inc

Riot Blockchain is trending as investors debate whether the recent dip is a buying opportunity, especially relative to competitors, and potential manipulation. Community members are closely watching Bitcoin's price movement and upcoming earnings, hoping for positive AI/HPC updates. Some traders express frustration with the stock's price action despite positive news and guidance.

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

Enveric Biosciences Inc

Enveric Biosciences ($ENVB) is trending as traders discuss its potential as the next short squeeze target, drawing comparisons to past Reddit favorites like $BYND and $AMC. Community chatter highlights the stock's low float and speculation around potential patent payouts, suggesting a possible catalyst for significant upward movement. Some traders are also pointing to recent videos made by YouTubers as a possible reason for the increased attention.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma ($FIG) is trending after its integration was showcased at the OpenAI DevDay, sparking community excitement about AI-driven design. Bullish investors believe the stock is undervalued compared to competitors like Adobe, while others are wary of its recent IPO and potential for further declines. Community members are actively discussing entry points and whether the OpenAI partnership can reshape Figma's future.

Lemonade, Inc. is a holding company, which engages in the provision of insurance services. The firm's products include renters and homeowners insurance, and pet insurance. It offers insurance coverage under the homeowners multi-peril, inland marine, and general liability lines of business. The company was founded by Daniel Asher Schreiber and Shai Wininger on June 17, 2015 and is headquartered in New York, NY.

Lemonade Inc

Lemonade Inc. is trending as the community discusses its recent post-earnings move and long-term potential, with some traders noting an overreaction and potential short squeeze while others express skepticism about its profitability. Community members are actively debating whether it can break through key resistance levels soon. Meanwhile, some traders are also monitoring ENVB for a potential short squeeze similar to Beyond Meat's earlier surge.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

MannKind ($MNKD) is trending as the community discusses the company's revenue potential and recent earnings, with many expressing bullish sentiment and anticipating future growth. Community members are excited about potential catalysts, including pipeline advancements and label expansion, and some are speculating about potential acquisitions. The stock's movement is also attributed to a potential short squeeze.

Digital Turbine, Inc. is a mobile growth platform that offers solutions for advertisers, publishers, carriers, and device original equipment manufacturers (OEMs). The firm operates through the On Device Solutions (ODS) and App Growth Platform (AGP) segments. The ODS segment generates revenue from the delivery of mobile application media or content to end users with solutions for all participants in the mobile application ecosystem that want to connect with end users and consumers who hold the device. This includes mobile carriers and device OEMs that participate in the app economy, app publishers and developers, and brands and advertising agencies. The AGP segment provides platforms that allow mobile app publishers and developers to monetize their monthly active users via display, native, and video advertising. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

Digital Turbine ($APPS) is trending as community members discuss the stock's potential, fueled by raised price targets and optimism around AI integration. Discussions also focus on whether $APPS can sustain gains after recent earnings, with some traders pointing to its history of post-earnings volatility. ENVB is getting some attention as a potential Reddit-driven short squeeze play as well.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SLS Median OS = when the KM curve hits 50%. You don’t need every patient at 30 months — you need ≥50% events. With staggered accrual and an 80-event OS endpoint, a ~30-month median is entirely feasible before the last patient reaches 30 months.
“63 alive at 30 months” is arithmetic fiction: median ≠ fixed headcount at a fixed time, and you can’t derive it without the KM curve.
Dr. T’s “2.5 years” was clearly a projection/benchmark, not a disclosed, unblinded study-wide mOS — the trial remains blinded until the 80-event analysis.
Bottom line: stop mixing timelines with medians. Facts &gt; made-up math.

Szepen

CS Liu

임성모

A Brave Lion

Philip

Roger Rabbit $5,56

EasyLode

Bottsy

The Wolf of Finland

Jeff

Terry

Anthony

Captain

Tony M

Sergey

Marc

durlas

Emzed

Chris

Randall J Koeppen

Chessdoc

ilcail

$SLS During the presentation Dr. T made a very clear comment about the REGAL trial having an mOS of 2.5 years. 
He was clear, but he clearly misspoke and I emailed John to see if the company would issue a comment. 
Assuming Dr. T was correct, 63 would have to be alive at 2.5 years and clearly that is impossible as we are just into the 25th month since 105 were enrolled and only now 20 months since the last.  
Coming up on 80 deaths means there is nowhere close to 63 alive at 30 months.  
It&#39;s assumed he meant the GPS arm would approach 30.

StockTwits Web

SELLAS Life Sciences Group Inc

Keith Thompson

$SLS no it&#39;s not realistic at all. 
What do you think would be BAT&#39;s 2yr survival rate? It would be less than 20% with conservative take and less than 10% more likely.  
 
This means 55 BAT patients pass away before 2yrs. There will be non-responders in GPS group and also non-AML related deaths. These patients will be mote than 20% of GPS group for sure. Unless BAT has way greater mOS, it is impossible for mOS of whole group to be 30mo. 
 
You don&#39;t need to draw a KM curve, since 63rd event would possively have happened early this year, January or Feb.

Lancarth

StockTwits for iOS

 Median OS = when the KM curve hits 50%. You don’t need every patient at 30 months — you need ≥50% events. With staggered accrual and an 80-event OS endpoint, a ~30-month median is entirely feasible before the last patient reaches 30 months.
“63 alive at 30 months” is arithmetic fiction: median ≠ fixed headcount at a fixed time, and you can’t derive it without the KM curve.
Dr. T’s “2.5 years” was clearly a projection/benchmark, not a disclosed, unblinded study-wide mOS — the trial remains blinded until the 80-event analysis.
Bottom line: stop mixing timelines with medians. Facts > made-up math.

Giada

@G_Trade @thompske I think it is totally realistic: what seems to be new info is that 30months is the mOS for the all pooled in Regal, so the &#39;63rd event&#39; happend after 30months...
We knew that the 60 patents pooled mOS was 13,5months, so the &#39;30th event&#39; happend after 13,5months...

StockTwits For Android 

 I think it is totally realistic: what seems to be new info is that 30months is the mOS for the all pooled in Regal, so the '63rd event' happend after 30months...
We knew that the 60 patents pooled mOS was 13,5months, so the '30th event' happend after 13,5months...

@Szepen @thompske No. Two basic errors.
 1. Median ≠ “63rd event.” Median OS is when the KM curve drops to 0.5. With staggered accrual + censoring, the 50% point is not the N/2-th death. The “63rd event” math is made-up.
 2. “All-pooled mOS = 30 months” is not disclosed. REGAL is triple-blind, event-driven; nobody has an official pooled mOS.
Also: a median at ~30 months doesn’t contradict reaching 80 events later — it just means &gt;50% of events occurred by ~30 months, and more events happened after (that’s how survival curves work).
Bottom line: stop inventing headcounts from medians and stop claiming pooled medians in a blinded trial. Facts &gt; speculation.

Persephonia

William

Alex

William B

 No. Two basic errors.
 1. Median ≠ “63rd event.” Median OS is when the KM curve drops to 0.5. With staggered accrual + censoring, the 50% point is not the N/2-th death. The “63rd event” math is made-up.
 2. “All-pooled mOS = 30 months” is not disclosed. REGAL is triple-blind, event-driven; nobody has an official pooled mOS.
Also: a median at ~30 months doesn’t contradict reaching 80 events later — it just means >50% of events occurred by ~30 months, and more events happened after (that’s how survival curves work).
Bottom line: stop inventing headcounts from medians and stop claiming pooled medians in a blinded trial. Facts > speculation.

@G_Trade you are so wrong here.  I fully know about the KM curve data and rolling time line. We know 21 have only been in the trial 19-24 months. So now you need 63 out of 105 to be alive at 30 months.  No matter when BAT enrolled very few of any are alive at their own 30 month mark.  How many of the 60 dead in December hit 30 months?

Paul Nipkow

Mister Anderson

 you are so wrong here.  I fully know about the KM curve data and rolling time line. We know 21 have only been in the trial 19-24 months. So now you need 63 out of 105 to be alive at 30 months.  No matter when BAT enrolled very few of any are alive at their own 30 month mark.  How many of the 60 dead in December hit 30 months?

@G_Trade @Szepen Wrong again. REGAL is an open label trial only blinded to the company, you should know that.  Doctors and patients know what they are getting.  Secondly, pooled mOS means 63 patients would have to be alive at their 30th month with the rolling enrollment, less any dropouts. So tell me how many BAT and GPS non responders would be expected to reach their 30th month?

 Wrong again. REGAL is an open label trial only blinded to the company, you should know that.  Doctors and patients know what they are getting.  Secondly, pooled mOS means 63 patients would have to be alive at their 30th month with the rolling enrollment, less any dropouts. So tell me how many BAT and GPS non responders would be expected to reach their 30th month?

@thompske Statistics aren’t optional.
Median OS is not about “63 out of 105 alive at 30 months.” It’s when the Kaplan–Meier curve crosses 50% — weighted by time, censoring, and staggered accrual. The 50% event mark doesn’t equal “the 63rd death.”

In an event-driven, triple-blind Phase 3 like REGAL, some patients have &lt;24 mo follow-up, some &gt;36 mo, all contributing partial time at risk. That’s exactly why median ≠ headcount math.

Also, you don’t know who’s alive in each arm — the trial is still blinded. The “60 dead by December” line is made-up; no such data exist in any filing or transcript.

Bottom line: learn how survival analysis works before building theories on imaginary body counts. The delayed 80-event trigger speaks louder — and it’s bullish.🤦🏻‍♀️🤦🏻‍♀️

 Statistics aren’t optional.
Median OS is not about “63 out of 105 alive at 30 months.” It’s when the Kaplan–Meier curve crosses 50% — weighted by time, censoring, and staggered accrual. The 50% event mark doesn’t equal “the 63rd death.”

In an event-driven, triple-blind Phase 3 like REGAL, some patients have <24 mo follow-up, some >36 mo, all contributing partial time at risk. That’s exactly why median ≠ headcount math.

Also, you don’t know who’s alive in each arm — the trial is still blinded. The “60 dead by December” line is made-up; no such data exist in any filing or transcript.

Bottom line: learn how survival analysis works before building theories on imaginary body counts. The delayed 80-event trigger speaks louder — and it’s bullish.🤦🏻‍♀️🤦🏻‍♀️

@G_Trade OMG, I give up with you. There is absolutely no way 50% are alive at their own 30th month. We absolutely know 60 were dead by early December, do you remember the IA trigger.  
You still don&#39;t get it. REGAL is NOT TRIPLE blind.

 OMG, I give up with you. There is absolutely no way 50% are alive at their own 30th month. We absolutely know 60 were dead by early December, do you remember the IA trigger.  
You still don't get it. REGAL is NOT TRIPLE blind.